Seoul, Republic of South Korea – September 15, 2026 – In a significant advancement for the treatment of advanced non-small cell lung cancer (NSCLC), Johnson & Johnson (J&J) has announced groundbreaking results from its Phase III PAPILLON study. The combination of Rybrevant (amivantamab-vmjw) and chemotherapy has demonstrated the longest median overall survival (OS) ever recorded in a Phase III trial for patients with NSCLC harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutations. This pivotal data, presented at the prestigious Presidential Symposium of the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), signifies a transformative step forward for a patient population historically facing grim prognoses.
The PAPILLON study, a randomized, multicenter trial, revealed that patients treated with the bispecific antibody Rybrevant in combination with chemotherapy achieved a median OS of an impressive 34.3 months. This figure stands in stark contrast to the 27.9 months observed in patients receiving chemotherapy alone. This nearly three-year median survival represents a substantial extension, offering patients significantly more time with their loved ones and a higher quality of life.
A New Era of Treatment for EGFR Exon 20 Insertion NSCLC
For years, NSCLC patients with EGFR Ex20ins mutations have been a particularly challenging group to treat. These specific mutations, which account for approximately 12% of all EGFR mutations, have historically been refractory to many targeted therapies that have proven effective against other EGFR alterations. The median OS for this patient group has typically ranged from a bleak 16 to 24 months, with five-year survival rates hovering at a mere 8%. The PAPILLON study’s findings shatter these historical benchmarks, ushering in a new era of therapeutic possibility.
The superior survival outcomes observed with the Rybrevant and chemotherapy combination are particularly noteworthy considering the trial design. A significant portion of patients in the chemotherapy arm (76%) elected to switch to Rybrevant as a second-line treatment following disease progression. Even with this substantial crossover, the Rybrevant-containing regimen demonstrated a remarkable extension in median OS. When a prespecified analysis accounted for this crossover, the risk of death was reduced by an impressive 43%, underscoring the profound and lasting benefit of the combination therapy.
Dr. Chul Kim, Director of Thoracic Oncology at MedStar Georgetown University Hospital and an investigator in the PAPILLON study, expressed his profound optimism. "We’ve come a long way in treating EGFR Ex20ins-positive lung cancer, and these results demonstrate the lasting impact RYBREVANT plus chemotherapy can have in helping patients live longer," Dr. Kim stated. "Patients are continuing treatment years after they started, which speaks to the durability of this approach and its value as a first-line treatment for this disease." His sentiments reflect the sentiment of the broader oncology community, recognizing the transformative potential of these findings.
Chronology of Progress: From Trial Design to Landmark Presentation
The journey leading to these groundbreaking results has been a testament to rigorous scientific investigation and commitment to improving patient outcomes. The PAPILLON study (NCT04538664) was meticulously designed to evaluate the efficacy and safety of Rybrevant in combination with chemotherapy as a first-line treatment for patients with advanced NSCLC and EGFR Ex20ins mutations.
The study’s primary endpoint was progression-free survival (PFS). In October 2023, J&J announced that the PAPILLON trial had met this crucial endpoint, demonstrating a statistically significant and clinically meaningful 60% improvement in PFS for the triplet arm compared to the doublet arm. The median PFS in the Rybrevant plus chemotherapy arm was 11.4 months, a substantial leap from the 6.7 months observed in the chemotherapy-only arm. This early success in delaying disease progression laid the groundwork for the eagerly anticipated overall survival data.
The presentation of the OS data at the IASLC 2026 WCLC in Seoul, Republic of South Korea, marks a pivotal moment in the study’s dissemination. Held from September 12th to 15th, the WCLC is one of the world’s premier scientific meetings dedicated to lung cancer research. The selection of these results for presentation at the Presidential Symposium, a segment reserved for the most impactful and innovative research, further underscores their significance. The visual representation of these findings, with accompanying imagery from the conference venue, highlights the global impact and scientific rigor behind this advancement.
Supporting Data: Beyond Survival to Durable Response
The positive outcomes extend beyond overall survival, with the progression-free survival data serving as a strong foundation. The 60% improvement in median PFS from 6.7 months to 11.4 months with the combination therapy indicates a significant delay in disease progression, allowing patients to experience a longer period without their cancer worsening. This is crucial for maintaining quality of life and enabling continued engagement with treatment.
Furthermore, the durability of response observed in the PAPILLON trial is a key differentiator. The fact that patients are continuing treatment for years after initiation, as highlighted by Dr. Kim, points to a sustained benefit and a favorable long-term tolerability profile for the Rybrevant combination. This sustained efficacy is particularly important for a chronic disease like advanced NSCLC, where long-term management is often the goal.
The safety profile of intravenous Rybrevant in the PAPILLON study remained consistent with previous research. The most commonly reported treatment-related adverse events (TEAEs) included paronychia (inflammation around the nail bed), neutropenia (low white blood cell count), and rash. While these side effects require careful monitoring and management, they are generally considered manageable and do not detract from the overall positive risk-benefit profile demonstrated by the efficacy data.
Official Responses and Regulatory Implications
Johnson & Johnson, through its Janssen Pharmaceutical Companies, has consistently championed the development of innovative therapies for unmet medical needs. The success of the PAPILLON study is a direct result of their commitment to advancing the treatment landscape for EGFR-mutated NSCLC. The company’s proactive engagement in presenting these findings at a leading international conference demonstrates their dedication to sharing vital scientific information with the global medical community.
This breakthrough has significant implications for regulatory approvals. J&J has already secured approvals for Rybrevant in patients with EGFR-mutated advanced NSCLC, encompassing both common mutations (exon 19 deletions and exon 21 L858R substitution mutations) and Ex20ins mutations, for both first- and second-line settings. The robust OS data from the PAPILLON study is expected to further solidify Rybrevant’s position as a cornerstone therapy for EGFR Ex20ins NSCLC and may pave the way for expanded indications or label enhancements. Oncologists worldwide will now have strong evidence to support the use of this combination as a preferred first-line treatment option.
Broader Market Implications and Future Outlook
The NSCLC therapeutics market is a dynamic and rapidly evolving sector. According to a report by GlobalData, the parent company of Clinical Trials Arena, the NSCLC therapeutics market across seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) was valued at an estimated $24.1 billion in 2022. This market is projected to experience substantial growth, reaching $56.5 billion by 2032, with a compound annual growth rate (CAGR) of 8.9%.
The introduction of highly effective treatments for previously underserved patient populations, such as those with EGFR Ex20ins mutations, is a significant driver of this market expansion. The demonstrated ability of Rybrevant plus chemotherapy to significantly extend overall survival and improve progression-free survival for these patients will undoubtedly contribute to this market growth. Furthermore, it underscores the increasing importance of precision medicine and the identification of specific genetic mutations to guide treatment decisions.
The success of the PAPILLON study not only benefits patients with EGFR Ex20ins mutations but also signals a broader trend in lung cancer treatment: the relentless pursuit of therapies that offer durable, long-term benefits. As research continues to unravel the complexities of NSCLC and identify novel therapeutic targets, Johnson & Johnson’s commitment to innovation, as exemplified by the development and validation of Rybrevant, offers a beacon of hope for countless patients worldwide. The extended survival achieved in this trial represents a monumental leap forward, transforming the outlook for a group of patients who have long been in critical need of more effective treatment options.
About the Author
